XML 71 R114.htm IDEA: XBRL DOCUMENT
v2.4.0.8

Collaborative and Other Relationships (Details) (USD $) | 3 Months Ended | 12 Months Ended
--- | --- | ---
Dec. 31, 2013 | Sep. 30, 2013 | Jun. 30, 2013 | Mar. 31, 2013 | Dec. 31, 2012 | Sep. 30, 2012 | Jun. 30, 2012 | Mar. 31, 2012 | Dec. 31, 2013 | Dec. 31, 2012 | Dec. 31, 2011
Revenues from unconsolidated joint business |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Revenue on sales in the rest of world for RITUXAN | $ 1,607,100,000 | [1],[2] | $ 1,453,600,000 | $ 1,385,900,000 | [3] | $ 1,095,800,000 | [4] | $ 1,074,700,000 | [5] | $ 1,039,100,000 | $ 1,076,800,000 | [6] | $ 975,400,000 | $ 5,542,331,000 | $ 4,166,074,000 | $ 3,836,117,000
Total unconsolidated joint business revenues | 269,400,000 | [1],[2] | 303,200,000 | 288,800,000 | [3] | 264,600,000 | [4] | 280,900,000 | [5] | 287,800,000 | 284,600,000 | [6] | 284,600,000 | 1,126,017,000 | 1,137,923,000 | 996,597,000
U.S |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Revenues from unconsolidated joint business |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Revenue on sales in the rest of world for RITUXAN |  |  |  |  |  |  |  |  |  |  |  |  |  | 3,581,000,000 | 2,176,800,000 | 1,954,800,000
Roche Group - Genentech |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Revenues from unconsolidated joint business |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Total unconsolidated joint business revenues |  |  |  |  |  |  |  |  |  |  |  |  |  | 1,126,000,000 | 1,137,900,000 | 996,600,000
Roche Group - Genentech | U.S |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Revenues from unconsolidated joint business |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Biogen Idec's share of pre-tax profits in the U.S. for RITUXAN and GAZYVA |  |  |  |  |  |  |  |  |  |  |  |  |  | 1,085,200,000 | 1,031,700,000 | 872,700,000
Reimbursement of our selling and development expenses in the U.S. for RITUXAN |  |  |  |  |  |  |  |  |  |  |  |  |  | 2,100,000 | 1,600,000 | 6,100,000
GAZYVA [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
After First GA101 Threshold Date |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Until First GAZYVA Threshold Date | 39.00% |  |  |  |  |  |  |  |  |  |  |  |  | 39.00% |  |
After First Threshold Date and until Second Threshold Date | 37.50% |  |  |  |  |  |  |  |  |  |  |  |  | 37.50% |  |
After Second Threshold Date | 35.00% |  |  |  |  |  |  |  |  |  |  |  |  | 35.00% |  |
RITUXAN |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Co-promotion profit sharing formula |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Until GAZYVA First Non-CLL FDA Approval | 40.00% |  |  |  |  |  |  |  |  |  |  |  |  | 40.00% |  |
After First GA101 Threshold Date |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Until First GAZYVA Threshold Date | 39.00% |  |  |  |  |  |  |  |  |  |  |  |  | 39.00% |  |
After First Threshold Date and until Second Threshold Date | 37.50% |  |  |  |  |  |  |  |  |  |  |  |  | 37.50% |  |
After Second Threshold Date | 35.00% |  |  |  |  |  |  |  |  |  |  |  |  | 35.00% |  |
RITUXAN | Roche Group - Genentech | Outside the U.S |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Revenues from unconsolidated joint business |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Revenue on sales in the rest of world for RITUXAN |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 38,700,000 | $ 104,600,000 | $ 117,800,000
[1] | Net income and net income attributable to Biogen Idec Inc. for the first quarter of 2012 includes a charge to research and development expense of $29.0 million related to an upfront payment made in connection with our development agreement entered into with Isis.
[2] | Net income and net income attributable to Biogen Idec Inc., for the third quarter of 2013, includes a charge to research and development expense of $75.0 million related to an upfront payment made in connection with our collaboration agreement entered into with Isis.
[3] | Product revenues and total revenues for the second, third and fourth quarters of 2013 includes 100% of net revenues related to sales of TYSABRI as a result of our acquisition of TYSABRI rights from Elan on April 2, 2013 and net revenues related to sales of TECFIDERA, our new oral first-line treatment for people with relapsing forms of multiple sclerosis (MS), which was approved by the FDA in March 2013 and commenced commercial sales in April 2013.
[4] | Our share of revenues from unconsolidated joint business reflects a charge of $41.5 million for damages and interest awarded to Hoechst in Genentech's arbitration with Hoechst for RITUXAN.
[5] | Net income and net income attributable to Biogen Idec Inc. for the fourth quarter of 2012 includes the correction of an error that had accumulated over several prior years in our deferred tax accounting for capitalized interest which resulted in an expense of $29.0 million.
[6] | Net income and net income attributable to Biogen Idec Inc. for the fourth quarter of 2012 includes a charge to research and development expense of $30.0 million related to an upfront payment made in connection with our development agreement entered into with Isis.

X
- Details
Name: | biib_CoPromotionProfitSharingFormulaAbstract
Namespace Prefix: | biib_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Percentage of co promotion operating profits greater than first fifty million option one. + References No definition available. + Details
Name: | biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionOne
Namespace Prefix: | biib_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | instant

X
- Details
Name: | biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoAbstract
Namespace Prefix: | biib_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Percentage of co promotion operating profits greater than first fifty million option two sub option one. + References No definition available. + Details
Name: | biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionOne
Namespace Prefix: | biib_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition Percentage of co promotion operating profits greater than first fifty million option two sub option three. + References No definition available. + Details
Name: | biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionThree
Namespace Prefix: | biib_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition Percentage of co promotion operating profits greater than first fifty million option two sub option two. + References No definition available. + Details
Name: | biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionTwo
Namespace Prefix: | biib_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition Reimbursement of selling and development expenses. + References No definition available. + Details
Name: | biib_ReimbursementOfSellingAndDevelopmentExpenses
Namespace Prefix: | biib_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | biib_RevenuesFromUnconsolidatedJointBusinessAbstract
Namespace Prefix: | biib_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Share of co promotion profits. + References No definition available. + Details
Name: | biib_ShareOfCoPromotionProfits
Namespace Prefix: | biib_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Revenues from unconsolidated joint business consists of our share of pre-tax co-promotion profits in the U.S.; reimbursement of selling and development expense in the U.S.; and revenue on sales of RITUXAN outside the U.S., which consist of our share of pre-tax co-promotion profits in Canada. + References No definition available. + Details
Name: | biib_UnconsolidatedJointBusiness
Namespace Prefix: | biib_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Aggregate revenue during the period from the sale of goods in the normal course of business, after deducting returns, allowances and discounts. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 225 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.1(a)) -URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 03 -Paragraph 1 -Article 5 + Details
Name: | us-gaap_SalesRevenueGoodsNet
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration